Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence

Nature Communications

Volumn 7, Issue , 2016, Pages

  Revandkar, Ajinkya ^a,b   Perciato, Maria Luna ^a   Toso, Alberto ^a   Alajati, Abdullah ^a   Chen, Jingjing ^a,b   Gerber, Hermeto ^c,d,e   Dimitrov, Mitko ^c   Rinaldi, Andrea ^a   Delaleu, Nicolas ^f   Pasquini, Emiliano ^a   D'Antuono, Rocco ^g   Pinton, Sandra ^a   Losa, Marco ^a   Gnetti, Letizia ^h   Arribas, Alberto ^a   Fraering, Patrick ^c,d,e   Bertoni, Francesco ^a   Nepveu, Alain ⁱ   Alimonti, Andrea ^a,b  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c EPFL   (Switzerland)

^d Foundation Eclosion   (Switzerland)

^e Campus Biotech Innovation Park ^*  (Switzerland)

^f UNIVERSITY OF BERGEN   (Norway)

^g INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; GAMMA SECRETASE; NIROGACESTAT; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27; UNCLASSIFIED DRUG; 2-(5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-3-YLAMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE; ADAM17 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PTEN PROTEIN, MOUSE; SECRETASE; TETRALIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VALINE;

CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; ENZYME ACTIVITY; INHIBITION; INHIBITOR; NUMERICAL MODEL; RODENT; SENESCENCE; TUMOR;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL AGING; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADAM17 PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; CELLULAR SENESCENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES; UP-REGULATION; VALINE;

EID: 85005949748     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13719     Document Type: Article

References (67)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Siegel, R. L., Miller, K. D., Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
3. Wu, X. et al. Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev. Biol. 356, 337-349 (2011).
4. Santagata, S. et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 64, 6854-6857 (2004).
5. Wang, Z. et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J. Cell. Biochem. 109, 726-736 (2010).
6. Yong, T., Sun, A., Henry, M. D., Meyers, S., Davis, J. N. Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells. J. Cell. Biochem. 112, 2340-2351 (2011).
7. Yu, Y. et al. Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation. Mol. Cancer Res. 12, 830-842 (2014).
8. Zayzafoon, M., Abdulkadir, S. A., McDonald, J. M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem. 279, 3662-3670 (2004).
9. Zhang, Y. et al. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int. J. Cancer 119, 2071-2077 (2006).
10. Zhu, H., Zhou, X., Redfield, S., Lewin, J., Miele, L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am. J. Transl. Res. 5, 368-378 (2013).
11. Domingo-Domenech, J. et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch-and Hedgehog-dependent tumorinitiating cells. Cancer Cell 22, 373-388 (2012).
12. Ross, A. E. et al. Gene expression pathways of high grade localized prostate cancer. Prostate 71, 1568-1578 (2011).
13. Bin Hafeez, B. et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin. Cancer Res. 15, 452-459 (2009).
14. Shou, J. Y., Ross, S., Koeppen, H., de Sauvage, F. J., Gao, W. Q. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res. 61, 7291-7297 (2001).
15. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
16. Maraver, A. et al. Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22, 222-234 (2012).
17. Radtke, F., Raj, K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat. Rev. Cancer 3, 756-767 (2003).
18. Roy, M., Pear, W. S., Aster, J. C. The multifaceted role of Notch in cancer. Curr. Opin. Genet. Dev. 17, 52-59 (2007).
19. Sulis, M. L., Saftig, P., Ferrando, A. A. Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia 25, 1564-1569 (2011).
20. Brou, C. et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216 (2000).
21. Mumm, J. S. et al. A ligand-induced extracellular cleavage regulates gammasecretase-like proteolytic activation of Notch1. Mol. Cell 5, 197-206 (2000).
22. Kopan, R., Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233 (2009).
23. Murphy, G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8, 929-941 (2008).
24. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
25. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997).
26. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
27. Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356-362 (1997).
28. Shen, M. M., Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000 (2010).
29. Alimonti, A. et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42, 454-U136 (2010).
30. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, 385-396 (2003).
31. Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203-1210 (2007).
32. Goulet, B. et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 14, 207-219 (2004).
33. Cadieux, C. et al. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer Res. 69, 7188-7197 (2009).
34. Moon, N. S., Berube, G., Nepveu, A. CCAAT displacement activity involves CUT repeats 1 and 2, not the CUT homeodomain. J. Biol. Chem. 275, 31325-31334 (2000).
35. Ramdzan, Z. M., Nepveu, A. CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers. Nat. Rev. Cancer 14, 673-682 (2014).
36. Chen, Z. B. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
37. Ranganathan, P., Weaver, K. L., Capobianco, A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 11, 338-351 (2011).
38. Olsauskas-Kuprys, R., Zlobin, A., Osipo, C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther. 6, 943-955 (2013).
39. Papayannidis, C. et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 5, e350 (2015).
40. Schouwey, K., Beermann, F. The Notch pathway: hair graying and pigment cell homeostasis. Histol. Histopathol. 23, 609-619 (2008).
41. Moriyama, M. et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J. Cell Biol. 173, 333-339 (2006).
42. Lin, H. K. et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379 (2010).
43. Yashiro-Ohtani, Y. et al. Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. Genes Dev. 23, 1665-1676 (2009).
44. Weng, A. P. et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20, 2096-2109 (2006).
45. Girard, L. et al. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 10, 1930-1944 (1996).
46. Robey, E. et al. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87, 483-492 (1996).
47. Cui, D. et al. Notch pathway inhibition using PF-03084014, a gamma-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin. Cancer Res. 21, 4619-4629 (2015).
48. Bray, S. J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 7, 678-689 (2006).
49. Bozkulak, E. C., Weinmaster, G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol. Cell. Biol. 29, 5679-5695 (2009).
50. Vadnais, C. et al. Long-range transcriptional regulation by the p110 CUX1 homeodomain protein on the ENCODE array. BMC Genomics 14, 258 (2013).
51. Toso, A. et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9, 75-89 (2014).
52. Skaar, J. R., Pagan, J. K., Pagano, M. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 13, 889-903 (2014).
53. Palumbo, A. et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann. Oncol. 19, 1160-1165 (2008).
54. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360 (2004).
55. Wang, Z. et al. Skp2: a novel potential therapeutic target for prostate cancer. Biochim. Biophys. Acta 1825, 11-17 (2012).
56. Szalad, A., Katakowski, M., Zheng, X., Jiang, F., Chopp, M. Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. J. Exp. Clin. Cancer Res. 28, 129 (2009).
57. Charbonneau, M. et al. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J. Biol. Chem. 282, 33714-33724 (2007).
58. Li, R. et al. High glucose up-regulates ADAM17 through HIF-1alpha in mesangial cells. J. Biol. Chem. 290, 21603-21614 (2015).
59. Mailly, F. et al. The human cut homeodomain protein can repress gene expression by two distinct mechanisms: active repression and competition for binding site occupancy. Mol. Cell. Biol. 16, 5346-5357 (1996).
60. Wong, C. C. et al. Inactivating CUX1 mutations promote tumorigenesis. Nat. Genet. 46, 33-38 (2014).
61. Cacquevel, M. et al. Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J. Neurochem. 104, 210-220 (2008).
62. Wu, F. et al. Novel gamma-secretase inhibitors uncover a common nucleotidebinding site in JAK3, SIRT2, and PS1. FASEB J. 24, 2464-2474 (2010).
63. Alattia, J. R. et al. Mercury is a direct and potent gamma-secretase inhibitor affecting Notch processing and development in Drosophila. FASEB J. 25, 2287-2295 (2011).
64. Thompson, M. A. et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum. Pathol. 36, 494-504 (2005).
65. Liberzon, A. et al. Molecular signatures database (MSigDB) 3. 0. Bioinformatics 27, 1739-1740 (2011).
66. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
67. Vilimas, T. et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med. 13, 70-77 (2007).